The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.70BUSD
vs all stocks (USD)
Updated Oct 27, 2026
Revenue (TTM)
69.67MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Profit Margin
-153.84%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Beta
2.32x
vs all stocks
Updated Oct 27, 2026
52-Week Change
64.82%
vs all stocks
Updated Oct 27, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 27, 2026
Market Capitalization
1.70BUSD
vs all stocks (USD)
Updated Oct 27, 2026
Enterprise Value
1.52BUSD
vs all stocks (USD)
Updated Oct 27, 2026
Forward P/E
-16.40x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Price to Sales (TTM)
24.29x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Price to Book (MRQ)
7.17x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Enterprise to Revenue
21.79x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Enterprise to EBITDA
-14.51x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Gross Margin
21.21%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 12.69%.Updated Oct 27, 2026
Profit Margin
-153.84%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Operating Margin
-150.25%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Return on Assets (TTM)
-25.03%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Return on Equity (TTM)
-50.32%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Revenue (TTM)
69.67MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Revenue per Share (TTM)
0.7130USDUpdated Oct 27, 2026
Quarterly Revenue Growth
30.00%
vs Diagnostics & Research peers
Updated Oct 27, 2026
Gross Profit (TTM)
8.84MUSD
vs all stocks (USD)
Updated Oct 27, 2026
EBITDA (TTM)
-104.60MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Net Income (TTM)
-107.18MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Operating Cash Flow (TTM)
-92.30MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Levered Free Cash Flow (TTM)
-56.03MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 27, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 27, 2026
Revenue
69.65MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
53.87MUSDFY2025 · Dec 31, 2025
Gross Profit
15.78MUSDFY2025 · Dec 31, 2025
Operating Income
-88.06MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-81.25MUSDFY2025 · Dec 31, 2025
Income Tax Expense
21.00KUSDFY2025 · Dec 31, 2025
Net Income
-81.27MUSDFY2025 · Dec 31, 2025
EBIT
-81.04MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-71.00MUSDFY2025 · Dec 31, 2025
Research & Development
50.26MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
53.57MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
7.16MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
205.00KUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.9100USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.9100USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
89.24MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
89.24MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-81.27MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-71.04MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-75.54MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
126.03MUSDFY2025 · Dec 31, 2025
Income Tax Paid
23.00KUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-81.27MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
10.05MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
9.43MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
1.03MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-8.06MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
4.55MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-6.76MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-4.50MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-210.17MUSDFY2025 · Dec 31, 2025
Sale of Investments
192.11MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-22.57MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
2.59MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-2.00MUSDFY2025 · Dec 31, 2025
Other Financing Charges
-189.00KUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
127.19MUSDFY2025 · Dec 31, 2025
Shares Outstanding
106.37MSharesUpdated Oct 27, 2026
Float Shares
86.37MSharesUpdated Oct 27, 2026
Shares Short
8.43MSharesUpdated Oct 27, 2026
Short Ratio
3.81days
vs all stocks
Updated Oct 27, 2026
Short % of Shares Outstanding
12.32%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 7.92%.Updated Oct 27, 2026
% Held by Insiders
25.64%
vs all stocks
Updated Oct 27, 2026
% Held by Institutions
65.56%
vs all stocks
Updated Oct 27, 2026
Total Cash (MRQ)
212.66MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Total Cash per Share (MRQ)
1.99USDUpdated Oct 27, 2026
Total Debt (MRQ)
38.00MUSD
vs all stocks (USD)
Updated Oct 27, 2026
Total Debt to Equity (MRQ)
0.1616x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Current Ratio (MRQ)
5.28x
vs Diagnostics & Research peers
Updated Oct 27, 2026
Book Value per Share (MRQ)
2.21USDUpdated Oct 27, 2026
Total Assets
334.16MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
267.95MUSDFY2025 · Dec 31, 2025
Total Liabilities
72.98MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
66.21MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
33.35MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
39.63MUSDFY2025 · Dec 31, 2025
Cash
4.92MUSDFY2025 · Dec 31, 2025
Cash Equivalents
119.33MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
124.25MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
115.71MUSDFY2025 · Dec 31, 2025
Accounts Receivable
16.20MUSDFY2025 · Dec 31, 2025
Inventory
5.26MUSDFY2025 · Dec 31, 2025
Accounts Payable
12.99MUSDFY2025 · Dec 31, 2025
Short-term Debt
8.08MUSDFY2025 · Dec 31, 2025
Deferred Revenue
1.56MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
5.46MUSDFY2025 · Dec 31, 2025
Long-term Debt
31.87MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.48MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-631.26MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
261.19MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
4.96USDUpdated Oct 27, 2026
52-Week High
18.89USDUpdated Oct 27, 2026
52-Week Change
64.82%
vs all stocks
Updated Oct 27, 2026
Beta
2.32x
vs all stocks
Updated Oct 27, 2026
50-Day MA
16.24USDUpdated Oct 27, 2026
200-Day MA
11.10USDUpdated Oct 27, 2026
Avg 10-Day Volume
2.69MSharesUpdated Oct 27, 2026
Avg 30-Day Volume
2.34MSharesUpdated Oct 27, 2026
Diluted EPS (TTM)
-1.09USDUpdated Oct 27, 2026
Other Income / Expense
-142.00KUSDFY2025 · Dec 31, 2025
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -50.3%, lower than 95% of its Diagnostics & Research peers (median 2.1%)Significant
Return on equity: -0.50Industry median: 0.02Industry P5: -0.24Peers compared: 27.00
Return on assets is -25%, lower than 95% of its Diagnostics & Research peers (median 1.2%)Significant
Return on assets: -0.25Industry median: 0.01Industry P5: -0.21Peers compared: 27.00